Vortioxetine

a novel antidepressant for the treatment of major depressive disorder

X. Gonda, Samata R. Sharma, Frank I. Tarazi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Introduction: Vortioxetine is a novel antidepressant drug approved for the treatment of major depressive disorder (MDD) in adults. It is formulated into tablets and has a dose range of 5–20 mg. The recommended starting dose is 10 mg administered orally once daily without the need for food. Areas covered: This review focuses on the preclinical and clinical discovery of vortioxetine. It analyzes the pharmacological, neurochemical, and behavioral mechanisms of the medication and how these contribute to its potential therapeutic advantages as described in published preclinical and clinical studies and product labels. Expert opinion: Vortioxetine displays high affinity for serotonin transporter (SERT), and serotonin 5-HT3, 5HT1A, 5HT7 receptors. Functional studies show that vortioxetine acts as a SERT blocker, a 5-HT3, 5-HT7 receptor antagonist, and a 5-HT1A receptor agonist. The drug is active in animal models predictive of antipsychotic and antidepressant activities and demonstrates procognitive effects in several animal models that assessed memory, cognition, and executive functions. Short- and long-term clinical trials demonstrated the clinical efficacy of vortioxetine in treating depressive symptoms and cognitive deficits in MDD patients. It also displays fairly benign safety and tolerability profiles. Vortioxetine’s unique psychopharmacological properties might contribute to an improved clinical outcome in MDD patient populations.

Original languageEnglish
Pages (from-to)81-89
Number of pages9
JournalExpert Opinion on Drug Discovery
Volume14
Issue number1
DOIs
Publication statusPublished - Jan 2 2019

Fingerprint

Major Depressive Disorder
Antidepressive Agents
Serotonin Plasma Membrane Transport Proteins
Therapeutics
Animal Models
Serotonin 5-HT1 Receptor Agonists
Receptor, Serotonin, 5-HT1A
Executive Function
Expert Testimony
Cognition
Antipsychotic Agents
Tablets
vortioxetine
Serotonin
Clinical Trials
Pharmacology
Depression
Safety
Food
Pharmaceutical Preparations

Keywords

  • Animal models
  • antidepressant drugs
  • clinical trials
  • cognition
  • major depressive disorder
  • serotonin receptors
  • serotonin transporters

ASJC Scopus subject areas

  • Drug Discovery

Cite this

Vortioxetine : a novel antidepressant for the treatment of major depressive disorder. / Gonda, X.; Sharma, Samata R.; Tarazi, Frank I.

In: Expert Opinion on Drug Discovery, Vol. 14, No. 1, 02.01.2019, p. 81-89.

Research output: Contribution to journalArticle

@article{b1a56eedce8c4e2f8b82a9a2c4390368,
title = "Vortioxetine: a novel antidepressant for the treatment of major depressive disorder",
abstract = "Introduction: Vortioxetine is a novel antidepressant drug approved for the treatment of major depressive disorder (MDD) in adults. It is formulated into tablets and has a dose range of 5–20 mg. The recommended starting dose is 10 mg administered orally once daily without the need for food. Areas covered: This review focuses on the preclinical and clinical discovery of vortioxetine. It analyzes the pharmacological, neurochemical, and behavioral mechanisms of the medication and how these contribute to its potential therapeutic advantages as described in published preclinical and clinical studies and product labels. Expert opinion: Vortioxetine displays high affinity for serotonin transporter (SERT), and serotonin 5-HT3, 5HT1A, 5HT7 receptors. Functional studies show that vortioxetine acts as a SERT blocker, a 5-HT3, 5-HT7 receptor antagonist, and a 5-HT1A receptor agonist. The drug is active in animal models predictive of antipsychotic and antidepressant activities and demonstrates procognitive effects in several animal models that assessed memory, cognition, and executive functions. Short- and long-term clinical trials demonstrated the clinical efficacy of vortioxetine in treating depressive symptoms and cognitive deficits in MDD patients. It also displays fairly benign safety and tolerability profiles. Vortioxetine’s unique psychopharmacological properties might contribute to an improved clinical outcome in MDD patient populations.",
keywords = "Animal models, antidepressant drugs, clinical trials, cognition, major depressive disorder, serotonin receptors, serotonin transporters",
author = "X. Gonda and Sharma, {Samata R.} and Tarazi, {Frank I.}",
year = "2019",
month = "1",
day = "2",
doi = "10.1080/17460441.2019.1546691",
language = "English",
volume = "14",
pages = "81--89",
journal = "Expert Opinion on Drug Discovery",
issn = "1746-0441",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Vortioxetine

T2 - a novel antidepressant for the treatment of major depressive disorder

AU - Gonda, X.

AU - Sharma, Samata R.

AU - Tarazi, Frank I.

PY - 2019/1/2

Y1 - 2019/1/2

N2 - Introduction: Vortioxetine is a novel antidepressant drug approved for the treatment of major depressive disorder (MDD) in adults. It is formulated into tablets and has a dose range of 5–20 mg. The recommended starting dose is 10 mg administered orally once daily without the need for food. Areas covered: This review focuses on the preclinical and clinical discovery of vortioxetine. It analyzes the pharmacological, neurochemical, and behavioral mechanisms of the medication and how these contribute to its potential therapeutic advantages as described in published preclinical and clinical studies and product labels. Expert opinion: Vortioxetine displays high affinity for serotonin transporter (SERT), and serotonin 5-HT3, 5HT1A, 5HT7 receptors. Functional studies show that vortioxetine acts as a SERT blocker, a 5-HT3, 5-HT7 receptor antagonist, and a 5-HT1A receptor agonist. The drug is active in animal models predictive of antipsychotic and antidepressant activities and demonstrates procognitive effects in several animal models that assessed memory, cognition, and executive functions. Short- and long-term clinical trials demonstrated the clinical efficacy of vortioxetine in treating depressive symptoms and cognitive deficits in MDD patients. It also displays fairly benign safety and tolerability profiles. Vortioxetine’s unique psychopharmacological properties might contribute to an improved clinical outcome in MDD patient populations.

AB - Introduction: Vortioxetine is a novel antidepressant drug approved for the treatment of major depressive disorder (MDD) in adults. It is formulated into tablets and has a dose range of 5–20 mg. The recommended starting dose is 10 mg administered orally once daily without the need for food. Areas covered: This review focuses on the preclinical and clinical discovery of vortioxetine. It analyzes the pharmacological, neurochemical, and behavioral mechanisms of the medication and how these contribute to its potential therapeutic advantages as described in published preclinical and clinical studies and product labels. Expert opinion: Vortioxetine displays high affinity for serotonin transporter (SERT), and serotonin 5-HT3, 5HT1A, 5HT7 receptors. Functional studies show that vortioxetine acts as a SERT blocker, a 5-HT3, 5-HT7 receptor antagonist, and a 5-HT1A receptor agonist. The drug is active in animal models predictive of antipsychotic and antidepressant activities and demonstrates procognitive effects in several animal models that assessed memory, cognition, and executive functions. Short- and long-term clinical trials demonstrated the clinical efficacy of vortioxetine in treating depressive symptoms and cognitive deficits in MDD patients. It also displays fairly benign safety and tolerability profiles. Vortioxetine’s unique psychopharmacological properties might contribute to an improved clinical outcome in MDD patient populations.

KW - Animal models

KW - antidepressant drugs

KW - clinical trials

KW - cognition

KW - major depressive disorder

KW - serotonin receptors

KW - serotonin transporters

UR - http://www.scopus.com/inward/record.url?scp=85057201168&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057201168&partnerID=8YFLogxK

U2 - 10.1080/17460441.2019.1546691

DO - 10.1080/17460441.2019.1546691

M3 - Article

VL - 14

SP - 81

EP - 89

JO - Expert Opinion on Drug Discovery

JF - Expert Opinion on Drug Discovery

SN - 1746-0441

IS - 1

ER -